Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

A. Murray Brunt; Duncan Wheatley; John Yarnold; Navita Somaiah; Stephen Kelly; Adrian Harnett; Charlotte Coles; Andrew Goodman; Amit Bahl; Mark Churn; Rada Zotova; Mark Sydenham; Clare L Griffin; James P Morden; Judith M Bliss; The FAST-Forward Trial Management Group

doi:10.1016/j.radonc.2016.02.027

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

A. Murray Brunt, Duncan Wheatley, John Yarnold, Navita Somaiah, Stephen Kelly, Adrian Harnett, Charlotte Coles, Andrew Goodman, Amit Bahl, Mark Churn, Rada Zotova, Mark Sydenham, Clare L Griffin, James P Morden, Judith M Bliss, The FAST-Forward Trial Management Group

Research output: Contribution to journal › Article (Academic Journal) › peer-review

185 Citations (Scopus)

328 Downloads (Pure)

Abstract

Background and purpose

FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.

Material and methods

Patients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.

Results

190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%); 26 Gy/5F 0/53.

Conclusions

Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.

Original language	English
Pages (from-to)	114-118
Number of pages	5
Journal	Radiotherapy and Oncology
Volume	120
Issue number	1
Early online date	1 Apr 2016
DOIs	https://doi.org/10.1016/j.radonc.2016.02.027
Publication status	Published - Jul 2016

Keywords

Breast cancer
Radiotherapy
Hypofractionation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.radonc.2016.02.027

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at http://www.sciencedirect.com/science/article/pii/S0167814016001158. Please refer to any applicable terms of use of the publisher.
Final published version, 444 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., Coles, C., Goodman, A., Bahl, A., Churn, M., Zotova, R., Sydenham, M., Griffin, C. L., Morden, J. P., Bliss, J. M., & The FAST-Forward Trial Management Group (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-118. https://doi.org/10.1016/j.radonc.2016.02.027

@article{83a3d633ca3946aea038b181b5834854,

title = "Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial",

abstract = "Background and purposeFAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.Material and methodsPatients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.Results190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%); 26 Gy/5F 0/53.ConclusionsAcute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.",

keywords = "Breast cancer, Radiotherapy, Hypofractionation",

author = "Brunt, {A. Murray} and Duncan Wheatley and John Yarnold and Navita Somaiah and Stephen Kelly and Adrian Harnett and Charlotte Coles and Andrew Goodman and Amit Bahl and Mark Churn and Rada Zotova and Mark Sydenham and Griffin, {Clare L} and Morden, {James P} and Bliss, {Judith M} and {The FAST-Forward Trial Management Group}",

year = "2016",

month = jul,

doi = "10.1016/j.radonc.2016.02.027",

language = "English",

volume = "120",

pages = "114--118",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Science Ireland",

number = "1",

}

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP, Bliss, JM & The FAST-Forward Trial Management Group 2016, 'Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial', Radiotherapy and Oncology, vol. 120, no. 1, pp. 114-118. https://doi.org/10.1016/j.radonc.2016.02.027

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. / Brunt, A. Murray; Wheatley, Duncan; Yarnold, John et al.
In: Radiotherapy and Oncology, Vol. 120, No. 1, 07.2016, p. 114-118.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

AU - Brunt, A. Murray

AU - Wheatley, Duncan

AU - Yarnold, John

AU - Somaiah, Navita

AU - Kelly, Stephen

AU - Harnett, Adrian

AU - Coles, Charlotte

AU - Goodman, Andrew

AU - Bahl, Amit

AU - Churn, Mark

AU - Zotova, Rada

AU - Sydenham, Mark

AU - Griffin, Clare L

AU - Morden, James P

AU - Bliss, Judith M

AU - The FAST-Forward Trial Management Group

PY - 2016/7

Y1 - 2016/7

N2 - Background and purposeFAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.Material and methodsPatients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.Results190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%); 26 Gy/5F 0/53.ConclusionsAcute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.

AB - Background and purposeFAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.Material and methodsPatients were randomly allocated to 40 Gy/15 fractions (F)/3-weeks, 27 Gy/5F/1-week or 26 Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4 weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4 weeks after completion.Results190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40 Gy/15F 6/44 (13.6%); 27 Gy/5F 5/51 (9.8%); 26 Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40 Gy/15F 0/43; 27 Gy/5F 1/41 (2.4%); 26 Gy/5F 0/53.ConclusionsAcute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.

KW - Breast cancer

KW - Radiotherapy

KW - Hypofractionation

U2 - 10.1016/j.radonc.2016.02.027

DO - 10.1016/j.radonc.2016.02.027

M3 - Article (Academic Journal)

C2 - 27046390

SN - 0167-8140

VL - 120

SP - 114

EP - 118

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 1

ER -

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this